Cargando…
Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin
The Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study (FLAGS) and the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) have shown that patients with advanced gastric cancer treat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627221/ https://www.ncbi.nlm.nih.gov/pubmed/31234436 http://dx.doi.org/10.3390/cancers11060871 |
_version_ | 1783434688702971904 |
---|---|
author | Takeuchi, Madoka Ajani, Jaffer A. Fang, Xuemin Pfeiffer, Per Takeuchi, Masahiro van Laarhoven, Hanneke W. M. |
author_facet | Takeuchi, Madoka Ajani, Jaffer A. Fang, Xuemin Pfeiffer, Per Takeuchi, Masahiro van Laarhoven, Hanneke W. M. |
author_sort | Takeuchi, Madoka |
collection | PubMed |
description | The Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study (FLAGS) and the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) have shown that patients with advanced gastric cancer treated with S-1/Cisplatin (CS) have similar overall survival (OS) compared to 5-fluorouracil/cisplatin (CF). The purpose of this analysis was to identify patients who may specifically benefit from CS using meta-enrichment analysis of the combined two datasets. Eleven clinico-pathological factors were selected and a high response enrichable population was determined. The efficacy of CS in the combined data set of 1365 patients (n = 1019 from FLAGS and n = 346 from DIGEST) was analyzed. We identified 683 patients (n = 374 from CS, n = 309 from CF) as the high response enrichable population who were classified as those with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1, more than two metastatic sites and low neutrophil-lymphocyte ratio (log(NL ratio)). In the high response enrichable population, the median OS in the CS group was 241 days compared to 210 days in the CF group (hazard ratio 0.776; 95% confidence interval 0.658 to 0.915; p-value 0.004). Through meta-enrichment analysis, the high response enrichable population to CS was identified. Our findings show the clinical importance of selecting the appropriate treatment based on specific patient characteristics. |
format | Online Article Text |
id | pubmed-6627221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66272212019-07-23 Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin Takeuchi, Madoka Ajani, Jaffer A. Fang, Xuemin Pfeiffer, Per Takeuchi, Masahiro van Laarhoven, Hanneke W. M. Cancers (Basel) Article The Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study (FLAGS) and the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) have shown that patients with advanced gastric cancer treated with S-1/Cisplatin (CS) have similar overall survival (OS) compared to 5-fluorouracil/cisplatin (CF). The purpose of this analysis was to identify patients who may specifically benefit from CS using meta-enrichment analysis of the combined two datasets. Eleven clinico-pathological factors were selected and a high response enrichable population was determined. The efficacy of CS in the combined data set of 1365 patients (n = 1019 from FLAGS and n = 346 from DIGEST) was analyzed. We identified 683 patients (n = 374 from CS, n = 309 from CF) as the high response enrichable population who were classified as those with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1, more than two metastatic sites and low neutrophil-lymphocyte ratio (log(NL ratio)). In the high response enrichable population, the median OS in the CS group was 241 days compared to 210 days in the CF group (hazard ratio 0.776; 95% confidence interval 0.658 to 0.915; p-value 0.004). Through meta-enrichment analysis, the high response enrichable population to CS was identified. Our findings show the clinical importance of selecting the appropriate treatment based on specific patient characteristics. MDPI 2019-06-21 /pmc/articles/PMC6627221/ /pubmed/31234436 http://dx.doi.org/10.3390/cancers11060871 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takeuchi, Madoka Ajani, Jaffer A. Fang, Xuemin Pfeiffer, Per Takeuchi, Masahiro van Laarhoven, Hanneke W. M. Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title_full | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title_fullStr | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title_full_unstemmed | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title_short | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
title_sort | meta-enrichment analyses to identify advanced gastric cancer patients who achieve a higher response to s-1/cisplatin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627221/ https://www.ncbi.nlm.nih.gov/pubmed/31234436 http://dx.doi.org/10.3390/cancers11060871 |
work_keys_str_mv | AT takeuchimadoka metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin AT ajanijaffera metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin AT fangxuemin metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin AT pfeifferper metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin AT takeuchimasahiro metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin AT vanlaarhovenhannekewm metaenrichmentanalysestoidentifyadvancedgastriccancerpatientswhoachieveahigherresponsetos1cisplatin |